FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SAN RAMON, Calif., Sept. 09, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation will take place on Tuesday, September 13, 2016 at 5:05 p.m. ET at The Lotte New York Palace Hotel, in New York, NY.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
